Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;5(6):844-849.
doi: 10.21037/tau.2016.08.15.

Off label therapies for testosterone replacement

Lorenzo DiGiorgio  1 , Hossein Sadeghi-Nejad  2
Affiliations
Review

Off label therapies for testosterone replacement

Lorenzo DiGiorgio et al. Transl Androl Urol. 2016 Dec.

Abstract

The incidence of hypogonadism has been steadily increasing over the last few years. Exogenous testosterone has been the standard treatment for hypogonadal men, but is associated with suppression of spermatogenesis as well as other possible adverse effects. There are other medications, currently considered "off label" for androgen replenishment, that exert their effect through modulation of the hypothalamic-gonadal axis. These medications increase endogenous testosterone levels and offer a different therapeutic approach. This review will focus on these alternative (off-label) therapies for androgen replacement in men.

Keywords: Hypogonadism; aromatase inhibitors (AIs); clomiphene citrate (CC); testosterone replacement.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Total testosterone levels at baseline, 6 and 12 weeks with clomiphene citrate and anastrozole. P<0.05 at 6 and 12 weeks (28).
Figure 2
Figure 2
Total testosterone to total estradiol ratio at baseline, 6 and 12 weeks with clomiphene citrate and anastrozole. P<0.05 at 6 and 12 weeks (28).
See this image and copyright information in PMC

References

    1. Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008;93:2737-45. 10.1210/jc.2007-1972 - DOI - PubMed
    1. Corona G, Vignozzi L, Sforza A, et al. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health 2013;31:103-25. 10.5534/wjmh.2013.31.2.103 - DOI - PMC - PubMed
    1. Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013;173:1465-6. 10.1001/jamainternmed.2013.6895 - DOI - PMC - PubMed
    1. Grech A, Breck J, Heidelbh J. Adverse effects of testosterone replacement therapy: an update on the evidence and controversy. Ther Adv Drug Saf 2014;5:190-200. 10.1177/2042098614548680 - DOI - PMC - PubMed
    1. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59. 10.1210/jc.2009-2354 - DOI - PubMed

LinkOut - more resources